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Background: Analysis of human monoclonal antibodies (mAbs) developed from HIV-1 infected donors have
enormously contributed to the identification of neutralization sensitive epitopes on the HIV-1 envelope
glycoprotein. The third variable region (V3) is a crucial target on gp120, primarily due to its involvement
in co-receptor (CXCR4 or CCR5) binding and presence of epitopes recognized by broadly neutralizing
antibodies.
Methods: Thirty-three HIV-1 seropositive drug naive patients (18 males and 15 females) within the age range
of 20–57 years (median = 33 years) were recruited in this study for mAb production. The mAbs were selected
from EBV transformed cultures with conformationally constrained Cholera-toxin-B containing V3C (V3C-CTB)
fusion protein. We tested the mAbs for their binding with HIV-1 derived proteins and peptides by ELISA and
for neutralization against HIV-1 viruses by TZM-bl assays.
Results: We isolated three anti-V3 mAbs, 277, 903 and 904 from the cells of different individuals. The ELISA
binding revealed a subtype-C and subtype-A specific binding of antibody 277 and 903 while mAb 904
exhibited cross reactivity also with subtype-B V3. Epitope mapping of mAbs with overlapping V3 peptides
showed exclusive binding to V3 crown. The antibodies displayed high and low neutralizing activity against
2/5 tier 1 and 1/6 tier 2 viruses respectively. Overall, we observed a resistance of the tier 2 viruses to
neutralization by the anti-V3 mAbs, despite the exposure of the epitopes recognized by these antibodies on
two representative native viruses (Du156.12 and JRFL), suggesting that the affinity of mAb might equally be
crucial for neutralization, as the epitope recognition.
Conclusions: Our study suggests that the anti-V3 antibodies derived from subtype-C infected Indian patients
display neutralization potential against tier 1 viruses while such activity may be limited against more resistant
tier 2 viruses. Defining the fine epitope specificities of these mAbs and further experimental manipulations will
be helpful in identification of epitopes, unique to clade C or shared with non-clade C viruses, in context of
V3 region.
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Table 1 Characteristics of the screening of EBV
transformed B-cell cultures with V3C-CTB
1Number of HIV-1 infected patients 33
2Total number of PBMCs isolated (million) 321.2
3Number of wells plated 3321
4Number of wells positive for V3-CTB 199
5Number of anti-V3 antibody secreting cell lines 3
133 HIV-1 infected drug naïve patient donor samples were recruited for
antibody production.
2A total of 321.2 million PBMCs were isolated from these 33 patients with a
mean of 9.72 million per individual (range = 1.7 to 30 million).
3The PBMCs were plated in 96 well tissue culture plates @ 80-100 k cells/well
and approximately 6% (199/3321) of the wells were positive with V3-CTB4.
5Three anti-V3 monoclonal antibody secreting clones 277, 903 and 904 were
stabilized.
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The non-covalently associated surface (gp120) and
transmembrane (gp41) subunits of the envelope glyco-
protein are decorated on the surface of Human Im-
munodeficiency Virus Type-1 (HIV-1) as a trimeric
spike [1], and serve as a target for broadly neutralizing
monoclonal antibodies (bNAbs) [2-4]. Because of its
involvement in the primary steps of receptor [5] and
co-receptor binding [6], the envelope gp120 has been
identified as a major target for HIV-1 NAbs [2,7-10].
However, the antigenic variability of exposed regions and
low immunogenicity of conserved domains on gp120
impose great challenges to identify the vulnerable tar-
gets on HIV-1 [2,4,11]. Nevertheless, the conserved epi-
topes on gp120 have been identified using antibodies
from neutralizing sera [12-14] and bNAbs [9,10,15-17],
which include the antibodies directed to the CD4 re-
ceptor binding site (CD4bs) and co-receptor binding
site mainly the third variable region (V3) [10,18-22].
The crystal structure of V3 resolved recently shows
that V3 protrudes ~30 Å from the CD4-bound gp120
core, and this extended structure can be divided into
three regions: the base (residues 1–8 and 25–35), the
stem (9–14 and 18–24) and the crown (residues 15–17)
(residue numbering w.r.t. V3) [23,24]. The V3 loop of
gp120 is highly antigenic in humans [25-28], and was
previously recognized as the principal neutralizing do-
main of HIV-1 [29]. However its role was shown to be
restricted to type specific viruses [30,31] and such an ob-
servation was supported by the extensive sequence vari-
ation in V3 from different viral isolates [32,33]. Given
the critical interaction with the co-receptors (CXCR4 or
CCR5) on host cells, V3 conventionally must retain
structurally conserved elements required for binding
[34,35]. More recently, studies have revealed that the V3
domain possesses conserved structural motifs despite
the sequence variation, and is often accessible on the
virus surface as a target for bNAbs [21,36-38].
Although, the V3 loop displays high structural conser-
vation, yet the degree of cross reactive anti-V3 antibody
response in individuals infected with diverse HIV-1 sub-
types varies substantially [39]. This difference in anti-
body response to V3 loop, has been shown to be
primarily determined by the four amino residues in the
V3 crown (GPGQ or GPGR), which mostly form a type
II β-turn [19,40]. Interestingly, the anti-V3 monoclonal
antibodies (mAbs) isolated from non-clade B infected
individuals, bearing GPGQ at the tip of V3 display better
neutralization capacity than subtype-B (having GPGR)
derived anti-V3 mAbs [19]. Such an observation was
substantiated by a study showing a high neutralization
potential of the anti-V3 mAbs derived from Cameroon
subjects infected with viruses harboring GPGQ (sub-
type-AG) at the V3 crown [21]. Further, in animmunization study carried out in rabbits with a gp120
DNA prime followed by a boost with various cholera
toxin B (CTB) fusion proteins containing the V3
sequences from different HIV-1 subtypes, the CTB fu-
sion protein containing a consensus-C (con-C) V3 se-
quence (V3C-CTB) (having a GPGQ motif at V3
crown), elicited a highly potent HIV-1 neutralizing re-
sponse compared to the other V3-CTB constructs [41].
A limited number of mAbs have been generated so far
against the HIV-1 subtype-C viruses including mAbs
against the V3 loop despite the fact that subtype-C
accounts for more than 50% of the global HIV-1 infec-
tions [42]. The only known human anti-V3 bNAb is
from a clade B infected patient [15]. Keeping in view the
above facts, we generated here three anti-V3 human
mAbs from HIV-1 infected Indian patients, using the
EBV immortalization method of human hybridoma tech-
nology. The functional analysis of the HIV-1 antibodies
generated in this study revealed cross reactive binding
and neutralization of the viruses tested.
Results
Characteristics of the anti-V3 mAbs generated from HIV-1
infected donors
A total of 3321 culture wells (96 well plate) of PBMCs
derived from 33 HIV-1 infected patients were estab-
lished. After 2–3 weeks, the culture supernatants of ap-
proximately 6% transformed wells tested positive for
reactivity with V3C-CTB (Table 1). Three heterohybrido-
mas producing anti-V3 mAbs were generated from dif-
ferent individuals (IDs; 277, 903 and 904). The mAbs
belong to IgG1 subclass with one (904) using a lambda
and the other two (277 and 903) with kappa light chain
genes. Interestingly, the kappa light chain Abs displayed
the same immunoglobulin heavy chain variable (IGHV)
gene usage (3-30*03) while the other Ab (904) showed
1-8*01 gene usage (Table 2). The complementarity deter-
mining region 3 for the heavy chain (CDRH3) were
Table 2 Immunogenetic analysis of human anti-V3
monoclonal antibodies
# 1mAb Specificity Isotype 2IGHV 3CDRH3
1 277 V3 (gp120) IgG1 κ 3-30*03 ATLPVVTPATEPFDF
2 903 V3 (gp120) IgG1 κ 3-30*03 AKHYAEGGLDV
3 904 V3 (gp120) IgG1 λ 1-8*01 ARFALQSYIVSTDSYDIDY
1Three anti-V3 monoclonal Abs listed were derived from HIV-1 infected Indian
donors.
2Immunoglobulin gene usage for heavy (IGHV) and amino acid sequences of
3CDRH3 domains was determined using IMGT system; an asterisk indicates
allele.
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(Table 2).
Cross reactive binding and epitope mapping of anti-V3
mAbs by ELISA
All the plasma samples from patients recruited for this
study, were previously screened for their relative binding
to V3C and V3B peptides (Andrabi et al., submitted)
and the data is here shown for only three samples from
which anti-V3 mAbs were isolated (Figure 1C). The pep-
tide binding assays revealed the cross reactive bindingFigure 1 Relative binding affinity of anti-V3 antibodies to HIV-1 deriv
derived from Indian donors (red) and 447-52D (an anti-V3 Ab isolated from
and B V3 peptides (1A), and subtype-C (Du156.12) and subtype-B (JRFL) de
tested by ELISA using mAbs at a concentration ranging from 10 to 0.00003
as negative control. Relative reactivity of anti-V3 plasma antibodies to cons
titers (Max50) for three patients from whom antibodies were generated (1C
binding while 903 displayed subtype-C specific binding.potential of the anti-V3 Abs in the plasma sample 277
and 904 while 903 showed subtype-C V3 specific
binding.
In order to determine the specificity of the anti-V3
mAbs generated from these three patients, we per-
formed the ELISA binding titration of the anti-V3
mAbs with recombinant envelope gp120 proteins and
HIV-1 derived peptides (Table 3). In addition to three
Indian anti-V3 mAbs, which were generated in this
study, we also tested the binding of an anti-V3 bNAb
(447-52D), isolated from a subtype-B HIV-1 infected
individual living in USA. The binding curves of mAbs
to con-C and B V3 peptides and subtype-C (Du156.12)
and B (JRFL) gp120 proteins are depicted in the rep-
resentative Figure 1. The mAbs were also tested with
a series of peptides and proteins for quality control
purpose and the 50% maximal binding (Max50) bind-
ing titers are summarized (Table 3). Overall, the
mAbs 277 and 903 showed binding to subtype-A or
C V3 while the antibody 904 also reacted with
subtype-B V3 region (Figure 1A-B, Table 3). We fur-
ther tested the mAbs by ELISA binding assays usinged peptides and proteins. The binding pattern of anti-V3 mAbs
HIV-1 subtype-B infected American individual) (green) to consensus-C
rived envelope gp120 proteins (1B). The binding of anti-V3 mAbs was
μg/ml (12 dilutions). Human anti-parvovirus B19 mAb 1418 was used
ensus-B and C V3 peptides is shown in terms of 50% ELISA binding
). Two plasma samples 277 and 904 showed cross clade reactive
Table 3 Binding of mAbs to subtype-A, B and C derived
HIV-1 proteins and peptides
2anti-V3 mAbs
1Protein/peptide Subtype I277 I903 I904 A447-52D 1418
Con-C V3 C 0.33 0.109 0.046 1.2 >10
Con-B V3 B >10 >10 0.623 0.323 >10
Du156.12 C 0.047 0.019 0.009 0.035 >10
JRFL B >10 >10 0.04 0.01 >10
92RW020 A 0.098 0.05 0.028 0.323 >10
SF162 B >10 >10 >10 0.004 >10
MN B >10 >10 2.27 0.011 >10
MPER C >10 >10 >10 >10 >10
IDR C >10 >10 >10 >10 >10
p24 B >10 >10 >10 >10 >10
BSA NA >10 >10 >10 >10 >10
PP NA >10 >10 >10 >10 >10
1List of recombinant proteins and peptides derived from subtype-A, B and C
HIV-1 viruses, NA: Not applicable.
2Four anti-V3 antibodies, three from IndianI (277, 903 and 904) and one from
AmericanA (447-52D) HIV-1 infected donor were tested for their relative
binding. The binding activity of anti-V3 mAbs against proteins and peptides
was tested by ELISA using mAbs at a concentration ranging from 10 to
0.00003 μg/ml (12 dilutions). The 50% binding titers (Max50, conc. μg/ml) of
each antibody against the corresponding protein or peptide is depicted as
numerical values in Bold (high affinity), Italic (low affinity) and >10, where
Max50 value was not reached. Human anti-parvovirus B19 mAb 1418 was
used as negative control. Each experiment was performed at least two
independent times.
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gion flanked with second constant (C2) and third con-
stant (C3) region of gp120, to identify the core epitope
recognized and found that all these anti-V3 mAbs,Table 4 Epitope mapping of anti-V3 mAbs with consensus-C V














1Amino acid sequences of linear overlapping peptides encompassing the third varia
(C3: (right)) constant regions and are aligned with the corresponding consensus-C g
2Four anti-V3 antibodies, three from IndianI (277, 903 and 904) and one from Amer
overlapping peptides by ELISA using mAbs at a concentration ranging from 10 to 0
The 50% binding titers (Max50, conc. μg/ml) of each antibody against the correspo
affinity) and >10, where Max50 value was not reached. Human anti-parvovirus B19
least two independent times.including mAb 447-52D, bind to the crown of V3 loop
(Table 4).
Binding of anti-V3 mAbs to HIV-1 native, intact virions
The binding of Abs to HIV-1 derived peptides or pro-
teins does not necessarily mean that these mAbs will be
able to bind intact viruses, which essentially present a
more native conformation. In order to address this pos-
sibility, we tested the anti-V3 mAbs for binding with
Du156.12 (subtype-C) and JRFL (subtype-B) viruses in
an intact virion binding assay. The two viruses
(Du156.12 and JRFL) were chosen for this experiment
on the basis of their V3 sequence similarity with the cor-
responding con-C and B V3 sequence (Figure 2C). Con-
sistent with the binding of anti-V3 mAbs to Du156.12
and JRFL derived envelope gp120 proteins, the three
mAbs showed differential binding affinity to intact vir-
ions, 904 displaying high affinity as compared with 277
and 903. In addition, the mAb 904 retained the cross-
reactive binding potential to the intact viruses, evident
from the binding pattern (Figure 2A). The experiment
was validated by testing the intact virion binding of anti-
V3 mAb 447-52D to SF162 virus, known to have a well
exposed V3 region and allows accessibility to Ab without
any interference [43-45]. The binding of 447-52D to
SF162 intact virus revealed a very high binding affinity
(more than five folds) of mAb 447-52D as compared to
binding of three anti-V3 mAbs to Du156.12 and JRFL at
equivalent viral concentration (i,e 25 ng/ml) (Figure 2A-
B). This differential binding of mAbs to intact virions
could also be attributed to the number of potential N-3 overlapping peptides
peptides 2anti-V3 mAbs
CNISEEKWNKTLQ 277 903 904 447-52D 1418
>10 >10 >10 >10 >10
>10 >10 >10 >10 >10
>10 >10 >10 >10 >10
>10 >10 >10 >10 >10
>10 >10 >10 0.049 >10
4.04 1.37 0.327 0.149 >10
>10 >10 >10 >10 >10
>10 >10 >10 >10 >10
>10 >10 >10 >10 >10
>10 >10 >10 >10 >10
>10 >10 >10 >10 >10
>10 >10 >10 >10 >10
ble region (V3: Underlined (middle)), flanked by second (C2: (left)) and third
p120 sequence.
icanA (447-52D) HIV-1 infected donor were tested for their binding to
.00003 μg/ml (12 dilutions).
nding peptides is depicted as numerical values in Bold (high affinity), Italic (low
mAb 1418 was used as negative control. Each experiment was performed at
Figure 2 Binding of anti-V3 mAbs to native viruses. Binding of anti-V3 MAbs to native, intact HIV-1 virions, Du156.12 (subtype-C) and JRFL
(subtype-B). The supernatants of the two viruses were used at a final p24 concentration of 25 ng/ml. Antibody 904 displayed binding to both
viruses (Du156.12 and JRFL), while antibodies 277 and 903 showed subtype-C (Du156.12) specific binding (A). The unrelated mAb 1418 against
parvovirus B19 served as a negative control.The anti-V3 mAb 447-52D (known to bind SF162, a clade-B virus) and SF162 were used to validate the
experiment. The binding of 447-52D to intact virus was performed by using a fixed concentration of antibody (10 μg/ml) with two-fold dilution
of SF162 virus starting with 50 ng/ml of virus (B). The virus capture is determined by measuring the level of p24 (picograms per milliliter) released
when bound virus is lysed with detergent. The viruses (Du156.12 and JRFL) were chosen for intact virion binding assay on the basis of their
resemblance to the consensus-B and C V3 loop sequences (C). The V3 sequence of these viruses is aligned with their corresponding consensus-C
and B V3 loop sequence using Seqpublish program (http://hiv.lanl.gov).
Table 5 Neutralization of HIV-1 viruses by anti-V3 mAbs
in TZM-bl assay
anti-V3 mAbs
# Virus ID Tier Clade 277 903 904 447-52D 1418
1 MW965 1 C 0.34 0.15 <0.1 <0.1 >30
2 DJ263 1 A 8.2 1.7 0.4 <0.1 >30
3 SF162 1 B >30 >30 >30 <0.1 >30
4 JR-CSF 1 B >30 >30 >30 0.3 >30
5 92RW009 1 A >30 >30 >30 >30 >30
6 HIV-001428 2 C >30 15.4 22.8 >30 >30
7 ZM109F.PB4 2 C >30 >30 >30 >30 >30
8 ZM233M.PB6 2 C >30 >30 >30 >30 >30
9 Du156.12 2 C >30 >30 >30 >30 >30
10 JRFL 2 B >30 >30 >30 20 >30
11 RHPA4259.7 2 B >30 >30 >30 >30 >30
The cross neutralizing activities of mAbs generated from Indian patients along
with 447-52D (also an anti-V3 antibody), were evaluated against the tier 1 and
2 subtype_A, B, C viruses indicated on the left. The antibodies are shown with
antibody IDs (numerical values in bold) at the top of each column. Human
anti-parvovirus B19 mAb 1418 was used as negative control. The numerical
values in the boxes below are the 50% neutralization titers (IC50) defined as
the concentration (μg/ml) of mAb which neutralized 50% of viral infection in
the assay. For clarity, this information is coded: IC50 < 1 μg/ml; (Bold), IC50 > 1
μg/ml; (Italic) and >30, where IC50 was not reached. Each experiment was
performed at least two independent times.
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(3 for SF162, while 6 and 7 PNGS for Du156.12 and
JRFL respectively) of these viruses [46]. Overall the
results suggest that the V3 epitopes recognized by three
anti-V3 mAbs were exposed on both Du156.12 and
JRFL, however mAbs 277 and 903 were not able to bind
JRFL due to their subtype-C specific binding activity.
Neutralization potential of anti-V3 Abs against HIV-1
subtype-A, B and C viruses
The anti-V3 mAbs were tested to assess their capacity to
neutralize a panel of eleven tier 1 and 2 viruses from dif-
ferent HIV-1 subtypes using the standard TZM-bl cell
assay. The anti-V3 mAbs showed effective neutralization
against two, a subtype-A (DJ263) and a subtype-C
(MW965), out of five tier 1 viruses while only one virus
(a subtype-C, HIV-001428) out of six tier 2 viruses was
neutralized by two of the mAbs (903 and 904) with rela-
tively low efficiency (Table 5). None of the Indian anti-
V3 mAbs were able to neutralize any of the subtype-B
viruses, despite antibody 904 showing cross reactive
binding, nevertheless, the number of viruses tested here
was limited. In contrast, the mAb 447-52D reached IC50
neutralization titers with 5/11 viruses tested, consistent
with the previous studies [15,19].
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Human monoclonal antibodies against the HIV-1 enve-
lope glycoproteins are useful tools in the structural and
functional analysis of the viral envelope and have crucial
roles in guiding the design of prophylactic anti-HIV vac-
cines. Despite a huge expansion of HIV-1 subtype-C
worldwide, the clade-C viruses remain to be one of the
least studied subtypes especially in terms of HIV-1 neu-
tralizing antibodies. Using the rationale from previous
studies showing that viruses with GPGQ residues at the
tip of the V3 crown of the HIV-1 envelope induce potent
and cross reactive NAbs as compared to viruses with
GPGR motif, we generated here three anti-V3 mAbs
from Indian donors presumably infected with subtype-C
viruses bearing GPGQ at the V3 crown [42]. The func-
tional analysis of the Abs generated reveals a potent
neutralization potential with tier 1 viruses while such ac-
tivity was limited with the tier 2 viruses tested.
The anti-V3 Abs were selected from EBV-transformed
B-cell cultures of 33 HIV-1 infected antiretroviral drug
naïve patients using V3C-CTB fusion protein [47]. The
advantage of using a conformationally constrained in-
stead of a linear V3 peptide for selection of mAbs from
cultures or as animal immunogens has been previously
demonstrated [36,41,48-50]. We found 1-25% (mean =
6%) of the transformed wells positive for binding with
V3C-CTB in the first screening. The characteristic na-
ture of the B-cells from HIV-1 infected subjects and the
conditions used to immortalize them apparently affects
the number and type of Ab-producing cell lines that
grow out [51]. The overall positive percentage of Ab se-
creting culture wells was relatively good and could be
attributed to the high titers of anti-V3 Ab reactivity of
the corresponding plasma [28]. In contrast to a high per-
centage of positive secretors in the initial screening, we
were able to stabilize only three (277, 903 and 904) anti-
V3 Ab producing B-cell clones. This loss could be in
part due to the outgrowth of the non-secretor B cells
over the secretor B cells in subsequent steps of second-
ary screening, cell fusion and dilution cloning process.
Moreover, the B cells from HIV-1 infected patients are
mostly dysfunctional and polyclonally activated [52], and
such properties have been associated with a low persist-
ence of EBV infectivity [51,53,54].
The amino acid sequence variation of V3 across the
various HIV-1 subtypes is often related to a differential
immune response focused to V3 which is expected to
originate due to the subtype specific conformational dif-
ferences in the V3 region [55,56]. For instance, the HIV-
1 V3 crown residues GPGQ in non-clade B and GPGR
in clade B viruses respectively are the major determi-
nants of Ab binding and neutralization [19,40]. Epitope
mapping of the anti-V3 Abs with overlapping V3 pep-
tides reveal that their core epitopes lie in the crownregion only. Indeed, the recent immunological and struc-
tural studies of anti-V3 mAbs have observed similar pat-
tern of binding, wherein essentially all the anti-V3 mAbs
bind to ~14 residues in the V3 crown [57-59]. Two of
our anti-V3 mAbs (277, 903) showed binding to
subtype-A or C but not to subtype-B derived proteins
and peptides while mAb 904 displayed cross reactive
binding with subtype-B as well. The binding pattern (in
context of clade specific or cross reactive V3 antibodies)
of the two anti-V3 mAbs 903 and 904 was similar to
binding of polyclonal anti-V3 plasma antibodies from
the respective patients, however it was different for mAb
277 in the context of the plasma Abs of this patient
(Figure 1A-C). The finding highlights the importance of
pre-screening of plasma for binding to peptides from
different viral subtypes prior to isolation of mAbs. One
plausible reason for the non-binding of mAb 277 to the
V3B peptide in contrast to its corresponding polyclonal
plasma may be attributed to the higher number of
subtype-C specific B-cell clones in the B cell repertoire
of this patient, as indicated by its very high binding to
V3C (Figure 1C). It may also partly be ascribed to biased
selection with a CTB construct containing only V3C se-
quence, which might allow it to preferentially pick up
the B cell clone with clade-C V3 specificity. Interest-
ingly, the anti-V3 mAbs 277 and 903, which show clade-
A or C (both having a common GPGQ crown motif )
specific binding use the same variable heavy chain gene
(VH3-30) whereas the cross reactive mAb 904 uses a dif-
ferent VH gene (Table 1). The finding suggests a pos-
sible association of antibody gene usage with epitope
specificity, however the number of the mAbs generated
in this study is too small for comparison. Remarkably, a
recent analysis of anti-HIV Abs has pointed out a prefer-
ential usage of VH5-51 gene usage of anti-V3 Abs [60],
and such a preference was later shown to define a con-
served antigenic structure within the V3 [61].
The Ab accessibility on the HIV-1 native virus is often
challenged by the glycosylation pattern and epitope
masking [39,62,63]. This effect has been particularly
recognized for the V3 region wherein the neighboring
regions including V1/V2 shield the epitopes recognized
by anti-V3 Abs [46]. Although studies have suggested
that the HIV-1 V3 loop remains accessible on most of
the viruses [36], however this information is limited to
subtype-B viruses and remains to be explored for other
subtypes. Consistent with the binding to gp120 proteins
(Du156.12 and JRFL), the three anti-V3 mAbs were able
to bind intact native virions with a similar binding pat-
tern (Figure 2A). The results suggest that V3 epitopes are
well exposed over the intact trimeric viruses (Du156.12
and JRFL), and these findings are highly supported by
previous work in the literature [36,43]. The rationale of
using same proteins (gp120) and its corresponding
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minimize the effect of both, the V3 loop sequence and
the neighboring regions, on the local and global orienta-
tion of V3 and on the subsequent binding of Abs.
The anti-V3 mAbs showed potent neutralizing activity
against subtype-A and C tier 1 viruses, however this ac-
tivity was restricted for tier 2, especially the subtype-B
viruses. The finding was intriguing given the ability of
the anti-V3 mAbs to bind to two representative intact
virions of subtype-B (JRFL) and subtype-C (Du156.12),
and yet failing to reach IC50 neutralization titers. How-
ever, it should be noted that mAbs 903 and 904 which
display a better affinity than 277, showed neutralization
of up to 19% at 30 μg/ml, though not reaching IC50
neutralization titers, with these viruses (data not shown).
Overall, the data suggest that higher concentrations of
these mAbs may be effective in neutralization, however
that needs to be confirmed in detail. Together, these
results suggest that effective concentrations for binding
and neutralization may vary substantially, and the high af-
finity binding by mAb might be critical for neutralization.
The data are highly supported by various studies con-
ducted previously [15,36].
Conclusions
We isolated here three anti-V3 mAbs from HIV-1
infected donors from India which can effectively
neutralize tier 1 viruses but are less effective with tier 2
viruses, however this needs to be confirmed by testing
them with a broader panel of viruses from different
HIV-1 subtypes. This study demonstrates the import-
ance of pre-screening of plasma Abs for cross reactive
binding, for production of mAbs and the idea can like-
wise be employed for other antigenic regions. Also the
study highlights the significance of the antibody affinity,
which may probably be equally important as its epitope
accessibility, for effective viral neutralization. Further-
more, the analysis of the mAbs generated in this study
will allow us to identify epitopes that are unique to clade
C viruses and also those that are shared with other sub-
types in the context of V3 loop, and the data may pro-
vide useful information for HIV-1 vaccine design.
Material and methods
Ethics statement
The study was approved by the ethics committee of All
India Institute of Medical Sciences (AIIMS) New Delhi,
and the written informed consent for research and pub-
lication of the data was obtained from all the
participants.
Study subjects
Thirty-three HIV-1 seropositive drug naive patients (18
males and 15 females) within the age range of 20–57 years (median = 33 years) were recruited in this study
from the Regional STD Teaching Training & Research
centre, Safdarjang Hospital, New Delhi, India during the
period 2008–2011. The patients had a median CD4
count of 449 (range = 203-966) cells/cubic millimeter
(Additional file 1: Table S1). The whole blood samples of
HIV-1 positive donors were collected in EDTA vacutai-
ners, plasma was separated by centrifugation at 300 g
and stored in aliquots at - 80°C until use. The plasma
samples were heat inactivated at 56°C for 1 h before
using in the assays. The patients have been previously
shown to have high titers of anti-V3 Abs in their plasma
and a good proportion of these V3 directed Abs dis-
played cross reactivity [28], (Andrabi et al., submitted).
Presumably, the patients were infected with subtype-C
viruses, which is a major subtype in India [64,65]. In-
deed, the envelope sequences (partial C2-C5 of envelope
gp120) of a few patients revealed that majority of the
patients were infected with subtype-C viruses (Andrabi
et al., submitted).
Generation of anti-V3 human mAbs
The mAbs were generated using cellular techniques as
previously described [66]. Briefly, peripheral blood
mononuclear cells (PBMCs) were EBV transformed in
96-well plates and cultured with a polyclonal B cell acti-
vator, CpG [67], which enhanced EBV infection and B
cell transformation. The wells containing Ab-producing
cells were identified by testing the culture supernatants
for binding activity to V3C-CTB [47]. Cells from wells
that test positive were expanded and fused with the het-
eromyeloma cell line SHM-D33 (ATCC; catalog no.
1668). The fused cells that continued to make functional
Abs were repeatedly cloned until monoclonality was
achieved. The Abs were purified from culture superna-
tants using Protein G affinity columns (GE Healthcare)
and concentration of the mAbs was determined by non-
commercial ELISA. The anti-V3 mAb 447-52D gener-
ated previously from a clade B infected individual and a
mAb 1418, specific to parvovirus B19 [68], were used as
control Abs in this study.
RT-PCR amplification of the Ig variable region of the
heavy chain genes
Nucleotide sequence of Ig variable genes of human anti-
V3 mAbs was determined as previously described
[60,61]. The messenger RNA was extracted from hybri-
doma cell lines producing anti-V3 mAbs and reverse
transcribed into cDNA using oligo dT primer. Amplifi-
cation of the variable fragment was performed by PCR
using different gene family-specific sets of primers and
cDNA as template. Five forward primers, VH 1/5 [50-
CAG GTG CAG CTG GTG CAG TCT GG-30], VH2
[50-CAG GTC AAC TTA AGG GAG TCT GG-30], VH3
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[50-CAG GTG CAG CTG CAG GAG TCG GG-30] and
VH6 [50-CAG GTA CAG CTG CAG CAG TCA GG-30]
were located at 50 end of V genes. Reverse primer [50-
CTTGGTGGARGCTGARGAGACGGTGACC-30] was
located at the 30 end of JH segment and up to 12 nucleo-
tides at the 50 of the constant region of IgG [69]. PCR
amplification was performed using cycling program of
2 min at 94°C, 35 cycles of 60s at 94°C, 60s at 56°C, and
90s at 72°C, followed 8 min at 72°C. Ethidium bromide-
stained 0.8% agarose gels were used to visualize the PCR
products. The bands of the appropriate size were excised
and cleaned with GeneElute Minus EtBr Spin Column
(Sigma, USA). PCR products were sequenced (Macrogen,
South Korea) in both directions using the primers ap-
plied for amplification. The sequence data were analyzed
using the International ImMunoGeneTics (IMGT) infor-
mation system (http://imgt.cines.fr).
Envelope proteins and peptides
Five recombinant gp120s representing sequences of
primary HIV-1 isolates from clade A, B and C (produced
in 293 cells) and a p24 protein were purchased from Im-
mune Technology Corp. (New York, NY). A set of 12
linear overlapping peptides (each 15mer with an 11
amino acid overlap or a 4 amino acid walk) corre-
sponding to the sequence of consensus subtype-C V3
gp120 and CEF Control Peptide Pool (PP) (Cat. No.
9808) were obtained from the NIH AIDS Research
and Reference Reagent Program (NIH, ARRRP). Two
full length (35mer) peptides corresponding to the
consensus-B (CTRPNNNTRKSIHIGPGRAFYTTGEIIG
DIRQAHC) (V3B) and con-C (CTRPNNNTRKSIRI
GPGQTFYATGDIIGDIRQAHC) (V3C) of V3 gp120, a
24mer con-C MPER (DLLALDSWKNLWNWFDITNW
LWYIK) and a 19mer con-C IDR (LGIWGCSGKLICT
TAVPWN) peptides of gp41 were selected from Los Alamos
HIV-1 sequence database (http://hiv.lanl.gov), and were
synthesized from Sigma Genosys, USA. The peptides were
HPLC purified to >95% purity (based on information pro-
vided by company). The V3-cholera toxin B (CTB) fusion
protein (V3C-CTB) and wild type CTB (WT-CTB) used for
screening of antibody cultures were kindly provided by Prof.
Susan Zolla Pazner from New York University School of
Medicine.
Binding assay
The binding activity of anti-V3 mAbs against gp120 pro-
teins and peptides (including the V3 overlapping pep-
tides) were tested by enzyme-linked immunosorbent
assay (ELISA) as described [18]. Briefly, ELISA plates
were coated overnight with protein or peptide at 1.0 μg/ml,
blocked with 2% bovine serum albumin (BSA) in PBS,
and then incubated with mAbs at a concentrationranging from 10 to 0.00003 μg/ml (12 dilutions). The
bound mAbs were detected by incubation with alkaline
phosphatase-conjugated goat anti-human IgG (γ specific)
(SouthernBiotech, Birmingham, AL) followed by adding
substrate to develop color and the plates were read at
405 nm. The relative affinities of mAbs were determined
by measuring the concentration of mAbs required for
50% maximal binding (Max50), defined when the binding
curve reached the saturation level as described [70].
The binding of mAbs to intact virions was determined
with a capture assay as previously described [71]. Briefly,
a 96-well plate was coated overnight at 4°C with goat
anti-human immunoglobulin G (IgG) Fc Abs (Sigma) at
4.0 μg/ml, and then anti-V3 human mAbs at a saturating
level of 10 μg/ml were added for 1.5 h incubation at
37°C. The plate was blocked with 0.5% BSA in phosphate-
buffered saline (PBS) containing 10% goat serum and
10 μg of human IgG/ml. The culture supernatant, con-
taining pseudotyped viruses (Du156.12 and JRFL) at a
p24 concentration of 25 ng/ml, and the two fold diluted
primary isolate (SF162) with a starting p24/ml concen-
tration of 50 ng were added. The plate was incubated
overnight at room temperature. Viruses captured by
immobilized mAbs were lysed with 1% Triton-X in PBS.
Between each step of the assay, the plate was washed with
PBS containing 0.05% Tween 20, pH 7.4. The p24 in the
virus lysate was quantified by using a commercial ELISA.
The anti-V3 Ab 447-52D and SF162, a subtype-B virus
known to be sensitive to most of anti-V3 Abs were used
as assay control while the human mAb, 1418, was used as
a negative control.
Primary isolates and pseudoviruses
Eleven HIV-1 subtype A, B and C viruses including five
primary isolates (MW965, DJ263, SF162, JR-CSF and
92RW009) and six pseudotyped viruses (HIV-001428,
ZM109F.PB4, ZM233M.PB6, Du156.12, JRFL and
RHPA4259.7) were used for this study. All the primary
viruses and envelope clones were obtained from the
NIH, ARRRP. The HIV-1 isolates were expanded by only
one cycle of growth on phytohemagglutinin (PHA) and
interleukin-2 (IL-2)-stimulated PBMCs, as described
previously [45] to avoid alterations in env sequences due
to multiple rounds of expansion. Pseudotyped viruses
were produced by co-transfection of the rev/env expres-
sion plasmid and an env-deficient HIV-1 backbone vec-
tor (pSG3ΔEnv) into exponentially dividing 293 T cells
(ATCC; catalog no. 11268), in 6-well tissue culture plates
(Corning Inc) using calcium phosphate (Promega Inc)
method. Pseudovirus-containing culture supernatants
were harvested 48 hours post transfection filtered
(0.45 μm pore size) and stored at −80°C in 1 ml aliquots.
The 50% tissue culture infectious dose (TCID50) was
determined in TZM-bl cells.
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Neutralization of viruses by anti-V3 mAbs was measured
as a reduction in luciferase gene expression after a single
round of infection of JC53bl-13 cells, also known as
TZM-bl cells (NIH, ARRRP; catalog no. 8129), with
viruses [72,73]. Briefly, 200 TCID50 of pseudovirus was
pre-incubated for 1 hr at 37°C, 5% CO2 in 96-well flat-
bottom culture plates, with serial dilutions of mAbs,
starting from 30 μg/ml. Freshly trypsinized TZM-bl cells
(10,000 cells in 100 μl of growth medium containing
DEAE Dextran and protease inhibitor indianavir (in case
of primary isolates only), were added to each well of the
mAb/virus mixtures in duplicates. One set of control
wells received cells plus pseudovirus (virus control) and
another set received cells only (background control).
After 48 hours of incubation at 37°C, 5% CO2, luciferase
activity was measured by using the Bright-Glo Luciferase
Assay System (Promega Inc.). The 50% inhibitory con-
centration of mAb (IC50) was determined at which rela-
tive luminescence units (RLU) were reduced 50%
compared to virus control wells.Additional file
Additional file 1: Table S1. Demographic and clinical data of 33 HIV-1
infected drug naive patients recruited for human monoclonal antibody
production.
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